Suzhou Zelgen Biopharmaceuticals Co.,ltd
Clinical trials sponsored by Suzhou Zelgen Biopharmaceuticals Co.,ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for tough cancers: experimental drug ZG006 enters human trials Results expected Sep 2026 (estimated)
- New hope for advanced cancer? experimental drug ZGGS18 enters human trials Results expected Nov 2026 (estimated)
- Healthy volunteers test two versions of experimental drug Results expected Feb 2027 (estimated)
- New drug duo targets tough lymphoma Results expected Apr 2027 (estimated)
- New combo aims to tackle lung cancer after immunotherapy fails Results expected Apr 2027 (estimated)
-
New immunotherapy combo put to the test in advanced liver cancer
Disease control Not yet recruitingResearchers are testing whether an experimental immunotherapy called ZG005, combined with bevacizumab, works better than the standard combination of sintilimab and bevacizumab for people with advanced hepatocellular carcinoma who have not yet received systemic treatment. The tria…
Phase 3 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug ZG006 takes on chemo in advanced cancer battle
Disease control Not yet recruitingThis study tests a new drug called ZG006 against standard chemotherapy for people with advanced neuroendocrine carcinoma, a type of cancer. About 240 adults who have already had other treatments will be randomly assigned to receive either ZG006 or a chemotherapy chosen by their d…
Phase 3 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC